SEC Filings

8-K
AVEXIS, INC. filed this Form 8-K on 12/13/2017
Entire Document
 

Looking Ahead: Upcoming Milestones 10 SMA Type 1 end-of-Phase 1 Meeting with FDA: On December 5, 2017, AveXis had an end-of-Phase 1 meeting with FDA with respect to AVXS-101 for SMA Type 1. The company anticipates providing an update on feedback from FDA following the receipt of the final meeting minutes in early January. SMA Type 1 EU Trial: AveXis incorporated EU specific Scientific Advice from the EMA into the protocol design and expects to initiate a pivotal trial of AVXS-101 in SMA Type 1 in the EU in the first half of 2018. Rett Syndrome and Genetic ALS Programs: AveXis anticipates providing an update on the progress and timelines of its early-stage programs in Rett Syndrome and genetic ALS in the first quarter of 2018. Upcoming milestones

GRAPHIC

 


© AveXis, Inc. All Rights Reserved.